Advertisement
Advertisement
http://www.eahad2015.com

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Genetic variability in response to clopidogrel therapy and its clinical implications

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Contemporary issues in atherothrombosis

DOI: http://dx.doi.org/10.1160/THS10-11-0747
Issue: 2011: 105/Supplement 1
Pages: S55-S59

Genetic variability in response to clopidogrel therapy and its clinical implications

L. Yukhanyan (1), M. K. Freynhofer (1), J. Siller-Matula (2), K. Schrör (3), K. Huber (4)

(1) 3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria; (2) Department of Cardiology, Medical University of Vienna, Vienna, Austria; (3) Institute for Pharmacology und Clinical Pharmacology, Heinrich-Heine-Universität, Düsseldorf, Germany; (4) 3rd Medical Department with Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria

Keywords

thrombosis, gene mutations, coronary syndrome, Antiplatelet agents

Summary

This article concentrates on individual genetic differences responsible for variations of action of clopidogrel, which have been found to be partially responsible for increased cardiovascular events in patients with coronary artery disease under dual antiplatelet therapy. According to these results, genotyping for the relevant gene polymorphisms, especially for the CYP2C19 loss-of-function alleles, has been discussed to be an effective method of individualising and optimising clopidogrel treatment. However, due to the facts that 1) there are no prospective studies demonstrating a clinical benefit of personalising antiplatelet therapy based on genotyping; 2) CYP2C19 polymorphisms account for only approximately 12% of variability in clopidogrel platelet response; 3) the positive predictive value of CYP2C19 loss-of-function polymorphisms for cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention is only approximately 12% – 20%; 4) it is likely that other clinical factors and risk constellations might be of greater clinical importance; and 5) it is unknown whether a specific genetic polymorphism is capable of influencing outcome for the individual patient; genetic profiling cannot be recommended for routine use at present but will remain of considerable scientific interest.

You may also be interested in...

1.
Thomas Cuisset1, Corinne Frere2, Jacques Quilici1, Pierre-Emmanuel Morange2, Noémie Saut2, Marie Romero-Barra2, Laurence Camoin3, Marc Lambert1, Irène Juhan-Vague2, Jean-Louis Bonnet1, Marie-Christine Alessi2

Thromb Haemost 2007 97 2: 212-217

http://dx.doi.org/10.1160/TH06-10-0583

2.

Muhammad R. Marwali, Jawahar L. Mehta

Thromb Haemost 2006 96 4: 401-406

http://dx.doi.org/10.1160/TH06-07-0385

3.

Theme Issue Article for Theme Issue "Platelets: basic mechanisms and translational implications"

J. D. McFadyen (1), S. P. Jackson (1)

Thromb Haemost 2013 110 5: 859-867

http://dx.doi.org/10.1160/TH13-05-0379